Fosamax-Related Osteonecrosis of the Jaw: Understanding the Biological Plausibility

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Literacy to Occupational Exposure Concerns

The legacy of general health and science communication has long emphasized the importance of understanding how systemic exposures can influence localized biological outcomes. In the context of bone health, public health messaging has historically focused on the benefits of maintaining skeletal integrity through nutrition and lifestyle, while also acknowledging that certain pharmaceutical interventions carry unintended risks. This foundational knowledge provides a necessary backdrop for examining more specific exposure scenarios. Transitioning from this broad health perspective, attention now turns to the occupational and clinical settings where sustained exposure to bisphosphonate compounds, such as those found in Fosamax, may occur. While the general public receives information about medication risks in a population-wide context, workers in healthcare and pharmaceutical manufacturing face distinct patterns of repeated contact with these agents. The shift in focus from general health literacy to occupational exposure concern requires recognizing that the duration, frequency, and route of exposure in professional environments differ markedly from typical patient use. This distinction is critical when considering how biological plausibility for adverse outcomes, such as osteonecrosis of the jaw, may be informed by occupational hygiene principles rather than solely by clinical prescribing guidelines. The bridge between these domains lies in applying established toxicological concepts to workplace settings, where cumulative exposure burdens warrant careful evaluation.

Biological Plausibility of Fosamax-Induced Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover and increases bone mass. However, this suppression of normal bone remodeling has been linked to a rare but serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, infection, and exposed bone that fails to heal within eight weeks after identification by a healthcare provider. Diagnosis is primarily clinical, often supported by imaging studies to rule out other causes such as metastatic disease or osteoradionecrosis. The biological plausibility linking Fosamax to ONJ is grounded in the drug's pharmacodynamic effects on bone metabolism. Bisphosphonates like alendronate accumulate in the skeleton, particularly at sites of high bone turnover, and are released over time. The jawbone undergoes constant remodeling due to mechanical stress from chewing and the presence of teeth, making it a site of relatively high bone turnover. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies in estrogen-deficient rats treated with alendronate have examined effects on the jawbone, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings suggest that bisphosphonate treatment alters the mechanical and material properties of the jawbone, potentially predisposing it to necrosis.

Mechanistic Pathways and Risk Factors

The mechanistic pathways proposed for Fosamax-induced ONJ include: (1) oversuppression of bone turnover, leading to accumulation of microdamage and inability to repair it; (2) anti-angiogenic effects that reduce blood supply to the jawbone; (3) direct toxicity to oral epithelial cells, impairing mucosal healing; and (4) alteration of immune responses, increasing susceptibility to infection. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of bisphosphonate therapy to minimize ONJ risk, and the limitations of use section notes that the optimal duration of use has not been determined, with consideration for drug discontinuation after 3 to 5 years for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations and Temporal Relationship

Causation considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a rare event that may not be captured in clinical trials. The timeline between exposure and documented harm can range from months to years, with risk increasing with longer duration of bisphosphonate use. In summary, the biological plausibility of Fosamax-related ONJ is supported by the drug's mechanism of action, which suppresses bone turnover and alters jawbone properties, as demonstrated in preclinical studies. The prescribing information includes warnings about this risk, but the rarity of the event and the lack of definitive data on optimal duration of therapy complicate risk assessment for individual patients. Affected patients should be evaluated for known risk factors and managed with appropriate dental care and consideration of drug discontinuation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the biological plausibility linking Fosamax to osteonecrosis of the jaw?

The biological plausibility is grounded in Fosamax's mechanism of action as a bisphosphonate that inhibits osteoclast-mediated bone resorption, leading to oversuppression of bone turnover. This can cause accumulation of microdamage, reduced blood supply via anti-angiogenic effects, direct toxicity to oral epithelial cells, and altered immune responses. Preclinical studies show that alendronate alters the mechanical and material properties of the jawbone, predisposing it to necrosis (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the known risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk increases with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.